Over 20,000 Takeda Employees Choose Four New Global CSR Initiatives to Promote Climate-Resilient Health Systems Across 94 Countries
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 23 2025
0mins
Source: Newsfilter
Takeda's New Collaborations: Takeda has committed JPY 4.6 billion (approx. USD 32.1 million) to four new Global Corporate Social Responsibility (CSR) partners, selected by over 20,000 employees, to enhance climate-resilient health systems in low- and middle-income countries.
Impact and Goals: The Global CSR Program aims to reach 53.7 million people in 94 countries by 2030, with a total contribution of JPY 33.4 billion (approx. USD 238.7 million) across 38 collaborations, focusing on improving healthcare access and addressing climate-related health risks.
Analyst Views on TAK
Wall Street analysts forecast TAK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TAK is 18.00 USD with a low forecast of 18.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 15.940
Low
18.00
Averages
18.00
High
18.00
Current: 15.940
Low
18.00
Averages
18.00
High
18.00
About TAK
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
